Cryoglobulinemia vasculitis (inflammation of blood vessels) is a disorder caused by the hepatitis C virus. The symptoms and health problems of cryoglobulinemia can be mild to moderate to severe and for some people cryoglobulinemia can be life-threatening. Treating cryoglobulinemia with direct-acting antiviral medications has been shown to improve the symptoms and complications of cryoglobulinemia and for some people successful HCV treatment can cure it.
This objective of this clinical trial is to treat and cure hepatitis C and measure the effect of curing hepatitis C on HCV-related cryoglobulinemia vasculitis.
France: Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
To view the entire clinical trial information, click here